Effect of Secretin in Functional Dyspepsia and Healthy Subjects

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-07

Study Completion Date

2019-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Insights into the pathophysiology of functional dyspepsia, with recent demonstration of inflammation with eosinophilia and mastocytosis in the duodenum (3, 6, 7), providing a possible lead toward reduced secretion of a potential mediator of post-prandial gastric accommodation, the gastrointestinal peptide hormone secretin. The dominant site of synthesis and secretion of this hormone are enteroendocrine S cells in the duodenum. Inflammation-induced damage to these cells could produce a deficiency. Since intraluminal acid is a prominent stimulant of S cell secretion, the attempts to treat functional dyspepsia with anti-secretory medications could actually exacerbate a secretin deficiency syndrome. This raises the possibility of the therapeutic use of a secretin agonist or a positive allosteric modulator of the secretin receptor for patients with functional dyspepsia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tradipitant for Functional Dyspepsia

NCT05653310

Functional Dyspepsia

ENROLLING_BY_INVITATION PHASE2

Clinical Course of Functional Dyspepsia and Factors Predicting Outcome in Patients Receiving Medication-based Treatment

NCT05513040

Functional Dyspepsia

RECRUITING

Intestinal Permeability in Children/Adolescents With Functional Dyspepsia

NCT00363597

Functional Dyspepsia

COMPLETED

An Exploratory Study Examining The Effects Of Taking GW679769 Once-Daily For 4 Days In Patients With Functional Dyspepsia

NCT00358410

Nonulcer Dyspepsia

COMPLETED PHASE2

A Study of Glutamine to Treat Intestinal Permeability in Functional Dyspepsia

NCT05655819

Functional Dyspepsia

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will utilize single photon emission computed tomography (SPECT) methodology and gamma scintigraphy present in the GI laboratory of the outpatient Clinical Research Unit to study fasting gastric volumes and postprandial gastric accommodation responses and gastric emptying rates of a standardized meal in patients with functional dyspepsia and healthy subjects. Both groups will be studied twice, using crossover design, once with administration of secretin and once with placebo.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dyspepsia Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy Controls: Secretin Then Placebo

Healthy subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.

Group Type EXPERIMENTAL

Human Secretin

Intervention Type DRUG

Injected once over one minute

Placebo

Intervention Type DRUG

Injected once over one minute

Healthy Controls: Placebo Then Secretin

Healthy subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.

Group Type EXPERIMENTAL

Human Secretin

Intervention Type DRUG

Injected once over one minute

Placebo

Intervention Type DRUG

Injected once over one minute

Functional Dyspepsia: Secretin Then Placebo

Functional Dyspepsia subjects first receive human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 2.

Group Type EXPERIMENTAL

Human Secretin

Intervention Type DRUG

Injected once over one minute

Placebo

Intervention Type DRUG

Injected once over one minute

Functional Dyspepsia: Placebo Then Secretin

Functional Dyspepsia subjects first receive placebo treatment (normal saline, matching Secretin dose) via IV over 1 min on Visit Day 1. After a 1 to 4 week washout period, they received the human Secretin 0.2 mcg/kg via IV over 1 min on Visit Day 2.

Group Type EXPERIMENTAL

Human Secretin

Intervention Type DRUG

Injected once over one minute

Placebo

Intervention Type DRUG

Injected once over one minute

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Human Secretin

Injected once over one minute

Intervention Type DRUG

Placebo

Injected once over one minute

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ChiRhoStim Normal Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to provide written informed consent prior to any study procedures and be willing and able to comply with study procedures
* No medical problems or chronic diseases, other than functional dyspepsia, for that group
* Body mass index of 18-35 kg/m2
* Female subjects must have negative urine pregnancy tests and must not be lactating prior to receiving study medication and radiation exposure. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. Female subjects unable to bear children must have this documented in the medical record \[i.e., tubal ligation, hysterectomy, or post-menopausal (defined as a minimum of one year since the last menstrual period)\].

Exclusion Criteria

* Unable or unwilling to provide informed consent or to comply with study procedures
* Diagnosis of other gastrointestinal diseases besides functional dyspepsia
* Structural or metabolic diseases that affect the GI system
* Unable to avoid the following over-the-counter medications 48 hours prior to the baseline period and throughout the study:

* Medications that alter GI transit or motor function including laxatives, magnesium and aluminum containing antacids, prokinetics, erythromycin, buspirone, clonidine, tricyclic antidepressants, and secretin-norepinephrine reuptake inhibitors
* Analgesic drugs including NSAIDs and COX-2 inhibitors
* NOTE: Stable doses of thyroid replacement, estrogen replacement, low-dose aspirin for cardio-protection, low stable dose antidepressants of the SSRI class, and birth control (but with adequate backup contraception, as drug interactions with birth control have not been conducted) are permissible.
* History of recent surgery (within 60 days of screening)
* Acute or chronic illness or history of illness which in the opinion of the investigator could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data, such as frequent angina, Class III or IV congestive heart failure, moderate impairment of renal or hepatic function, poorly controlled diabetes, etc.
* Any clinically significant abnormalities on physical examination or laboratory abnormalities identified in the medical record, as determined by the investigator
* Acute GI illness within 48 hours of initiation of the baseline period
* Females who are pregnant or breastfeeding
* History of excessive alcohol use or substance abuse
* Participation in an investigational study within the 30 days prior to dosing in the present study
* Any other reason, which in the opinion of the investigator, would confound proper interpretation of the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes